ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1722

Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases
Abstract Number: 1364

Machine Learning-Driven Models for Disease Activity Prediction and Therapeutic Response Evaluation in Rheumatoid Arthritis Patients: An Analysis of Data from the Multicentre, Prospective, Egyptian Collage of Rheumatology (ECR) Study Group
Abstract Number: 0279

Macrophage Intracellular Fates of Monosodium Urate and Calcium Pyrophosphate Crystals: Phagocytosis, Exchanged/expulsion and Dissolution of Crystals
Abstract Number: 0759

Macrophage-Lineage Cells in Giant Cell Arteritis Express MMP12, Phagocytosis and Osteoclast-associated Molecules That May Contribute to Destruction of the Tunica Media
Abstract Number: 0451

Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome
Abstract Number: 0926

Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Abstract Number: 0925

Macrophages Produce Bone Anabolic Factors in Settings of Inflammation-Induced Bone Formation
Abstract Number: 1635

Magnetic Resonance Imaging for Therapy Monitoring in Giant Cell Arteritis – Impact on Disease Management
Abstract Number: 1367

Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
Abstract Number: 0204

Making Rheum for Palliative Care in Rheumatology: Perspectives of Rheumatology and Palliative Care Clinicians
Abstract Number: 0433

Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study
Abstract Number: 1908

Male Sex, Medical Comorbidity and Post-procedure Complications Are Associated with Higher In-hospital Mortality After Primary Total Knee Arthroplasty for Osteoarthritis
Abstract Number: 0989

Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Abstract Number: 0726

Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review
Abstract Number: 0516

Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].